Immunovant Inc

NASDAQ:IMVTUnited States

Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.

Contact Information

Headquarters

320 West 37Th StreetNEW YORK, NY, United States 10018

Phone

917-580-3099

Fax

302-636-5454

Executives

Executive Chairman of the Board

Frank Torti

Chief Executive Office, Director

Peter Salzmann

Chief Financial Officer

Eva Barnett

Chief Technology Officer

Jay Stout

Chief Development Officer

Julia Butchko